Get started
PFIZER INCPFIZER INCPFIZER INC

PFIZER INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

PFE trade ideas

$PFE Ready for Bottom Fishing?NYSE:PFE is certainly a dog but, it has put in a higher low and the moving averages are starting to turn up. I like to go bottom fishing occasionally. PFE is my new candidate. I have an alert set just above the current price where it may move above short-term resistance, around the thin blue line. If it triggers and I take this trade, I can put a stop close by at either the day low or the previous day’s low. All TBD. Ideas, not investing / trading advice. Comments always welcome. Thanks for looking.
NYSE:PFELong
by jaxdog
8
Thinking abou Pfizer. Trade on Weeks charts.Hello. In searching of trade of Quarter and+ Thinking about PFE. Last Year Was be for this stock is in -43% and in 2022 Y was be -13%. This Year starting to searching a levels of support by -5% 27,35 and -10% 29.911. As we can se on the Week chart like a double touch in this levels. Idea is so - If to get some stock to buy we can hold by stop levels on to 23.02 (-20% by Y) and Profits near find about 35,98 - 37,42 (+25-30% by Y) and after take a profits.... waiting to down to levels about 31,66 and 32,53 (+10% and +13% by Y). Also we have a trades in inside bar by the 11 dec 2023. Its my thinking about trade by this stock. What Do You thinking about It? Thank for Reading. Regards
NYSE:PFELong
by OpnTrader
Turning point for Pfizer, up or down?This is a turning point for this stock, where there are possibilieties for both sides to enter. If there will be agressive buyers or agressive sellers, depends also on overal situation on the market. Personally I´m giving 70% chance for long and 30% for short position. If you have decided to trade it, don´t enter on the entry line, wait for retests (long or short) and enter just if retest is done. I will update this trade if-when entry conditions are met. Wish you good luck.
NYSE:PFELong
by Rendon1
Pfizer - Watch The SupportHello Traders, welcome to today's analysis of Pfizer. -------- Explanation of my video analysis: All the way back in 2012 Pfizer created a massively bullish triangle reversal pattern at the $17.00 level. This was followed by a +200% rally. Since 2022 Pfizer has been dropping significantly and is now retesting the support level which I mentioned in the analysis. If we see bullish conformation on the smaller timeframes, this might be an interesting long trading setup. -------- I will only take a trade if all the rules of my strategy are satisfied. Let me know in the comment section below if you have any questions. Keep your long term vision.
NYSE:PFE
by basictradingtv
7
PFE Consevartive Trend TradeConservative Trend Trade 1F + long impulse + JOC test level + 1/2 correction + biggest untested volume Sp Calculated affordable stop loss (virtual if it hits the alarm I'll put a limit order to break even and if it doesn't reach it I'll HODL with dividends till original take profit) 1 to 2 R/R take profit with possible extension to 1/2 for monthly range Monthly context + long balance - expanding ICE + 1/2 correction + biggest volume manipulation without result
NYSE:PFELong
by MishaSuvorov
1
Pfizer's Surprising Turnaround: A Resilient JourneyIn an unexpected twist, Pfizer ( NYSE:PFE ), the U.S. pharmaceutical giant, has defied market expectations by reporting a surprise quarterly profit. This surprising turnaround can be attributed to the resilient demand for COVID-related products, outperforming the company's own projections. The earnings report for the fourth quarter revealed adjusted earnings of 10 cents per share, a stark contrast to the anticipated loss of 22 cents per share by analysts. Pandemic Fallout and Pfizer's Struggles: Investors had been skeptical about Pfizer's ( NYSE:PFE ) prospects as pandemic concerns waned and substantial revenues from COVID vaccine and treatment sales dwindled. The company faced an additional setback with its experimental obesity drug, contributing to a further decline in its stock value. This downturn reached levels reminiscent of the pandemic sell-off in 2020, resulting in a staggering $100 billion loss in market capitalization in 2023. Resilient COVID Product Demand: The silver lining for Pfizer ( NYSE:PFE ) emerged from the sustained demand for its COVID products, namely the antiviral treatment Paxlovid and the widely-used COVID vaccine Comirnaty, developed in collaboration with German partner BioNTech. Despite a significant drop in revenue from $57 billion in 2022 to $12.5 billion in 2023, these products played a crucial role in Pfizer's unexpected profitability. Strategic Initiatives for Recovery: To counter the adverse market trends, Pfizer ( NYSE:PFE ) has embarked on a strategic journey aimed at regaining profitability. A $4 billion cost-cutting program and internal restructuring form the cornerstone of the company's recovery plan. With these measures in place, Pfizer ( NYSE:PFE ) is optimistic about driving revenue growth through its cancer treatments, particularly following the $43 billion acquisition of cancer drugmaker Seagen. Additionally, the introduction of a new RSV vaccine is poised to contribute to the company's resurgence. Outlook and Future Projections: Pfizer's ( NYSE:PFE ) bold move to cut costs and refocus on high-potential areas, such as cancer treatments and vaccine development, has instilled confidence among investors. The company's projections for 2023 include an expected $1 billion in Paxlovid sales and $11.5 billion in Comirnaty sales. This outlook, combined with a 1.9% rise in premarket trading, suggests that Pfizer's strategic initiatives are resonating positively with the market. Conclusion: Pfizer's ( NYSE:PFE ) unexpected quarterly profit signifies a notable turnaround for the pharmaceutical giant. The company's ability to adapt to changing market dynamics, capitalize on resilient product demand, and implement strategic measures for recovery underscores its resilience. As Pfizer ( NYSE:PFE ) charts a course toward profitability, investors and industry observers are keenly watching how the company's strategic initiatives will shape its future in a post-pandemic landscape.
NYSE:PFELong
by DEXWireNews
Opportunity on PFEA viewer on my Livestream Friday brought to my attention that Pfizer NYSE:PFE is coming off a major low (COVID Low) and has done a pullback to the 50% of the Impulse Move off said low. This is why I love doing Livestreams and having a trading community... idea crowdsourcing! I like these setups especially as the S&P 500 and many stocks within it are making new 52 Week highs leaving many wondering "what's a good reward/risk at this point?" The pullback on the Weekly bring price to the 50% of what I call an "Impulse Move" off the low: the first major reaction to confirm that price is respecting a low. See the Daily chart below for a lower timeframe view: I would not want to hold the position if price breached the major low. My first Target would be the 50% Retracement of the Bearish trend at 40.32. This sets up a proper 3 to 1 Reward/Risk Ratio. I will likely express this trade with shares purchased but may seek to buy Calls as well.
NYSE:PFELong
by norok
6
PFE chart: TRENDS and Price TARGETSPFE chart - Mid term/Longer term Pretty bullish overall, but there is some downside showing (24, 18) These points make some excellent buy zones. Watch that first rejection trend Really strong rejection trend at the top (thick red) I'm liking 54 as an exit, but there is potential to fly past that. Idk, I think at some point we see the downside of 18-17, but I'm sure when. If it happens sooner rather than later, strong buy. Remember, you can wait for the price to go under your target and then buy when it starts going up to your target, or you can try and catch the falling knife. Good luck!
NYSE:PFELong
by nicktussing77
Health Canada Approval of ABRYSV Paves the Way for Pfizer In a significant stride towards enhancing public health, Health Canada has recently granted approval for Pfizer's groundbreaking bivalent Respiratory Syncytial Virus (RSV) vaccine, ABRYSVO™. This development is a crucial step in safeguarding both older adults and infants through maternal immunization. With the potential to revolutionize preventive healthcare, ABRYSVO™ addresses the prevention of lower respiratory tract diseases caused by RSV, catering to individuals aged 60 and above and infants from birth through 6 months. Protecting the Vulnerable Populations: The approval of ABRYSVO™ presents a new and vital option for protecting individuals most susceptible to severe RSV infections. Infants, particularly those under one year, face an increased risk of hospitalization due to RSV infection. Older adults also bear a significant burden of costs associated with the disease. Pfizer's vaccine aims to provide a comprehensive solution, mitigating the impact of RSV across different age groups and reducing the strain on healthcare resources. Maternal Immunization as a Strategic Approach: Dr. Darine El-Chaâr, a Maternal Fetal Medicine physician at The Ottawa Hospital, emphasizes the critical role of maternal immunization in bridging the vulnerability gap during the first few months of an infant's life. By administering vaccines to pregnant individuals, the approach not only protects the newborns but also safeguards mothers who may face an increased risk of severe disease compared to non-pregnant women. This strategic approach aligns with Pfizer's commitment to making a positive contribution to public health and community well-being. Pfizer's Commitment to Public Health: Andréa Mueller, Primary Care Portfolio Lead at Pfizer Canada, expresses pride in Pfizer's decades-long experience in vaccine development. The company's commitment to public health is evident in its dedication to providing effective solutions for preventing illness and reducing the strain on healthcare systems. The approval of ABRYSVO™ represents Pfizer's ongoing commitment to advancing healthcare solutions and making a positive impact on global well-being. Market Analysis: While the approval of ABRYSVO™ marks a significant milestone for Pfizer's contribution to public health, the technical analysis of Pfizer's stock indicates a falling trend channel in the medium to long term. Investors appear to have sold at lower prices over time, reflecting negative sentiments towards the company. However, it's essential to note that market trends are dynamic, and the approval of a groundbreaking vaccine may influence investor perceptions in the future. Conclusion: Pfizer's Health Canada approval for ABRYSVO™ brings hope for enhanced protection against RSV infections, benefiting both older adults and infants. The strategic focus on maternal immunization highlights Pfizer's commitment to addressing healthcare challenges comprehensively. As the company works towards making ABRYSVO™ available to Canadians, the market will likely closely watch how this groundbreaking vaccine contributes not only to public health but also to Pfizer's future trajectory in the pharmaceutical landscape.
NYSE:PFE
by DEXWireNews
PFE opportunity or value trap?I have been following PFE for a while last year and almost added it as a staple to my core dividend portfolio which is about 25% of my long-term investing portfolio. The stock just printed its first whole bodied green candle since December of two years ago. The RSI is at historical levels not seen since 2009. The PE ratio has expanded a bit but still offers some multiple expansion here. With a dividend over 5% and the stock having a huge margin of safety, this could be a strong bet to outperform money markets and provide a decent return. The stock rides the lower end of the Bollinger bands, it also saw 9 straight down months last year, similar to Verizon. I am very close to adding a huge chunk here before 30$. Even a 10% return this year with that 5% dividend is a win in these unsure markets.
NYSE:PFELong
by Apollo_21mil
PFE Pfizer Inc STRONG BUYPFE Pfizer, a darling of the Covid pandemic era is currently down from 56$ Pfizer emerged as a significant beneficiary during the Covid-19 era, witnessing a surge in its stock price. However, as the Covid-19 concern recedes, its share price has also returned most of its gains. Nevertheless, Pfizer's success isn't solely dependent on a single event, as it possesses a diverse portfolio of drugs that contribute to a more varied revenue stream. Although the Covid-19 vaccines brought substantial profits to Pfizer, its resilience lies in its broader pharmaceutical offerings. Morningstar has provided a fair valuation of $48, indicating a potential upside of 46%. Conservatives target are at $36 - $42 still a massive upside opportunity
NYSE:PFELong
by Gold_D_Roger